Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dofetilide
Drug ID BADD_D00701
Description Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Indications and Usage For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Marketing Status approved; investigational
ATC Code C01BD04
DrugBank ID DB00204
KEGG ID D00647
MeSH ID C063533
PubChem ID 71329
TTD Drug ID D0NW3X
NDC Product Code 0069-5810; 51862-005; 69452-133; 63190-0670; 42291-413; 42794-044; 51862-125; 14096-192; 29902-0014; 42291-411; 69452-131; 72205-041; 72664-229; 49812-0261; 16714-842; 42794-046; 47335-061; 47335-063; 59651-120; 72603-130; 72603-132; 16714-840; 16729-490; 16729-492; 59651-118; 69539-131; 0069-5820; 69452-132; 72664-231; 0904-6681; 50137-4245; 42291-412; 42794-045; 51862-025; 59651-119; 69539-130; 72664-230; 0904-6682; 0904-6683; 59651-038; 63190-0680; 0069-5800; 72205-040; 42413-0170; 63278-1079; 76055-0013; 16714-841; 16729-491; 69539-132; 72205-039; 72603-131; 69766-022; 47335-062
UNII R4Z9X1N2ND
Synonyms dofetilide | 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane | 1-MSPMPE | Tikosyn | UK 68798 | UK-68,798
Chemical Information
Molecular Formula C19H27N3O5S2
CAS Registry Number 115256-11-6
SMILES CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cholangiocarcinoma16.07.01.002; 09.04.02.0090.000085%Not Available
Cholelithiasis09.03.01.0020.000085%Not Available
Chronic obstructive pulmonary disease22.03.01.0070.000795%Not Available
Circulatory collapse24.06.02.0010.000085%Not Available
Condition aggravated08.01.03.0040.000770%Not Available
Coronary artery disease02.02.01.001; 24.04.04.0060.000127%Not Available
Cough22.02.03.0010.001404%
Deafness04.02.01.0010.000085%Not Available
Death08.04.01.0010.005540%
Dehydration14.05.05.0010.000355%
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.000085%Not Available
Disturbance in attention19.21.02.002; 17.03.03.0010.000431%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.0010.002453%Not Available
Drug ineffective08.06.01.0060.010301%Not Available
Drug interaction08.06.03.0010.000829%Not Available
Dysphagia07.01.06.0030.004736%
Dyspnoea22.02.01.004; 02.11.05.0030.002410%
Dyspnoea exertional02.11.05.005; 22.02.01.0050.000702%Not Available
Essential hypertension24.08.02.0080.000127%Not Available
Euphoric mood19.04.02.0060.000431%
Extrasystoles02.03.02.0030.000085%Not Available
Facial paralysis17.04.03.008--Not Available
Fatigue08.01.01.0020.004017%
Feeling abnormal08.01.09.0140.001049%Not Available
Flatulence07.01.04.0020.000186%
Fluid retention20.01.02.003; 14.05.06.0020.000228%Not Available
Gastrooesophageal reflux disease07.02.02.0030.000372%
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene